Hermann A. M. Mucke (born 4 September 1955) is an Austrian bioscientist with a peer-review publishing record in the fields of molecular biology, neuropsychiatry, cardiology and ophthalmology, mostly from the perspective of drug development.
This earliest plant molecular biology phase of Mucke's work concerned the characterization and partial sequencing of the Cyanophora cyanelle genome,[1][2][3] believed to resemble early stages of chloroplast evolution according to the endosymbiotic theory.
[5] A human T-lymphotropic virus antibody test, developed by Mucke's team but never marketed, served to demonstrate the first evidence of retrovirus-like serological reactivity in patients with the myelodysplastic syndrome,[6][7] a finding that meanwhile has been corroborated on the genomic level.
His most recent papers demonstrate a systematic utilization of patent documents as a source of information in science, technology, and market research in the fields of ophthalmology,[13][14] renal[15][16] and cardiorespiratory medicine, especially pulmonary hypertension,[17] and endothelin receptor antagonists.
[23] Hermann Mucke is Patent Editor at the Thomson Reuters journal, Current Opinion in Investigational Drugs [24] and an advisor to the Antiviral Spot of Excellence Vienna (ASPEX).